Eloxx Pharmaceuticals, Inc. (ELOX): Insider Trading, Congress Trades & Research | Tormere

ELOX

$12.92+0.62%

Eloxx Pharmaceuticals, Inc.

Market Cap

$52M

Live price × SEC shares (Aug 7, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

—

Insufficient price history

P/E (TTM)

N/M

TTM to Dec 2025 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Dec 2025 · negative equity

EV/EBITDA (TTM)

N/M

TTM to Dec 2025 · negative EBITDA

Loading…

Financial Statements

USD thousands	Mar 2025 Mar 31, 2025	Jun 2025 Jun 30, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	510	898	1,659	2,840
Total operating expenses	1,222	1,582	3,795	4,450
Operating income	(1,222)	(1,582)	(3,795)	(4,450)
Interest expense	500	300	100	100
Net income	(1,709)	(1,891)	(3,754)	(4,502)
EPS (basic) ($)	(5.40)	(5.45)	(0.96)	(0.66)	—
EPS (diluted) ($)	(5.40)	(5.45)	(0.96)	(0.66)	—
Weighted avg. shares (basic)	317	347	4,018	6,789
Weighted avg. shares (diluted)	317	347	4,018	6,789

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 11, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 54 more quarters, back to Sep 2010, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference

Yahoo · 2026-11-02

Eloxx's CEO is set to speak at 11:30 a.m. on Nov. 9.

Stock Titan · 2026-11-02

Eloxx Pharmaceuticals, Inc. (ELOX) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-10-30

ELOX: Eloxx Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits · 2026-10-29

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

Yahoo · 2026-10-29

Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40

Benzinga · 2026-10-28

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Yahoo · 2026-10-20

Eloxx Pharmaceuticals Finalizes Design For Its EXPRESS Phase 2 Global Trial In Nonsense-Mutation Autosomal Dominant Polycystic Kidney Disease To Enrolol 60 Adults With Genetically Confirmed PKD1 Or PKD2 Nonsense Mutations

Benzinga · 2026-10-20

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

Yahoo · 2026-10-19

A former Pfizer executive joins Eloxx's board

Stock Titan · 2026-10-19

This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Benzinga · 2026-10-15

Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating

Benzinga · 2026-10-15

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Yahoo Finance · 2026-09-11

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Yahoo Finance · 2026-08-12

ELOX Forecast — Price Target — Prediction for 2027

TradingView · 2026-07-26

Informational purposes only, not investment advice.

Corporate Events (8-K)

4 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 22, 2026 accepted 11:31 PM ET	5.02Officer / director change8.01Other events	Document SEC ↗
Aug 11, 2026 accepted 9:19 PM ET	2.02Earnings release	Document SEC ↗
Jun 1, 2026 accepted 11:00 AM ET	3.02Unregistered equity sale3.03Holder rights modified5.02Officer / director change5.03Bylaws / fiscal year	Document SEC ↗
May 1, 2026 accepted 8:05 PM ET	5.07Shareholder vote	Document SEC ↗
Aug 12, 2025 accepted 9:22 PM ET	5.02Officer / director change	Document SEC ↗